ArticleScientific reports2025
Exploration of plasma exosomal miR-122-5p and its related targets KNG1 and C3 in the diagnosis of drug-resistant tuberculosis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Role of Exosomes During Mycobacterium Tuberculosis Infection: A Double-Edged Sword.Biomedicines · 2026Review
- PstS1-loaded exosomes promote Mycobacterium tuberculosis infection via miR-122-mediated PI3K/AKT/mTOR activation and autophagy suppression.In vitro cellular & developmental biology. Animal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Drug-resistant tuberculosis (DR-TB) poses significant challenges not only to public health but also imposes substantial psychological and economic burdens on individuals and their families. As a severe infectious disease that jeopardizes both physical and mental well-being, DR-TB frequently spreads in underdeveloped regions due to inadequate diagnostic technologies.In this study, we validated the binding interaction between miR-122-5p and the proteins kininogen-1 (KNG1)/complement C3 using a dual-luciferase reporter assay. Furthermore, we employed liquid biopsy techniques to quantify miR-122-5p expression in plasma exosomes from DR-TB patients, alongside measuring plasma levels of KNG1, complement C3, and other coagulation and immune function parameters. This approach aims to identify efficient, non-invasive laboratory biomarkers for the early diagnosis of DR-TB. 50 patients with drug-susceptible tuberculosis (DS-TB) and 50 patients with DR-TB who were diagnosed in the nearby hospital between April 2024 and January 2025 were chosen. 51 healthy people who had physical exams over the same time frame were also selected as the control group. In the early morning, 5 ml of fasting venous blood was drawn from each of all subjects and centrifuged for standby. Informed consent was obtained from all Participants, who then signed the informed consent forms. We used Western blotting (WB), transmission electron microscopy (TEM), and nanoparticle tracking analysis (NTA) to find the biomarkers in the exosomes that were taken from each of the three groups' plasma. The dual-luciferase experiment was used to verify the targeting relationship between miR-122-5p and protein KNG1 and complement C3. The RNA level of the miR-122-5p gene in plasma exosomes was detected by real-time fluorescence quantitative PCR (qRT-PCR). The KNG1 level in the plasma of the subjects was measured by ELISA, and the clinical indicators of the patients were also collected. To assess the diagnostic effectiveness of the genes found in the plasma exosomes, we used the receiver operating characteristic (ROC) curve. We found that there is a targeting relationship between miR-122-5p and protein KNG1 as well as complement C3. Meanwhile, the level of miR-122-5p in the DR-TB group was significantly higher than that in the DS-TB group and the HCs group, indicating a relatively high diagnostic efficacy. A useful biomarker to enhance the diagnosis of DR-TB is the level of miR-122-5p in plasma exosomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.